FDA Advisory Panel Recommends 6 of 7 Peptides for Compounding: BPC-157, TB-500, KPV Clear July 2026 PCAC Vote

What this means for your practice

For telehealth brands, med spas, GLP-1 clinics, and longevity practices, the July 2026 PCAC votes signal a regulatory door beginning to open — but not yet open. Until the FDA completes formal rulemaking, these peptides are not lawfully compoundable, and any program that sources them from "research-use-only" vendors carries unapproved-drug and misbranding exposure that is now being prosecuted criminally. The compliant move is to prepare the infrastructure — licensed prescribers, valid patient-specific prescriptions, and vetted 503A pharmacy relationships — so you can operate lawfully the moment the pathway finalizes, rather than getting ahead of it. TrueEval helps operators build exactly that structure.

The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) met on July 23 and 24, 2026, at the agency's White Oak campus and voted on whether seven nominated peptides should be added to the Section 503A Bulk Drug Substances List — the federal list of substances that state-licensed pharmacies may compound for patients who have a valid prescription.

In a series of narrow votes, the committee recommended six of the seven peptides for inclusion and rejected one. Notably, the panel broke with the FDA's own scientific staff, who had recommended against adding all seven in pre-meeting briefing documents.

How the committee voted

Day 1 (July 23):

• BPC-157 (free base and acetate) — recommended, 8 to 6 with 1 abstention
• KPV — recommended, 8 to 6 with 1 abstention
• TB-500 (thymosin beta-4 fragment) — recommended, 8 to 6 with 1 abstention
• MOTS-c — recommended, 7 to 5 with 2 abstentions

Day 2 (July 24):

• Semax — recommended, 8 to 5
• Epitalon — recommended, 7 to 4
• Emideltide (DSIP) — rejected, 6 to 7 with 1 abstention

Important: a recommendation is not a green light

These votes are advisory and non-binding. They do not make any peptide an FDA-approved drug, do not establish that any peptide is safe or effective, and do not — on their own — make these substances legal to compound. Three separate legal events are easy to confuse:

• Removal from Category 2 (which the FDA did earlier in 2026 for this group of peptides) simply cleared them for committee review. It did not place them on the compounding list.
• A PCAC recommendation (what happened July 23-24) is the committee's advice to the FDA.
• Placement on the 503A list — the step that would actually authorize compounding — requires formal notice-and-comment rulemaking, which commonly takes many months to well over a year.

What it means for the "research-use-only" market

None of this changes the status of peptides sold online labeled "research use only" or "not for human consumption." The FDA's consistent position is that a product marketed or sold for human use is an unapproved, misbranded drug regardless of that disclaimer — and enforcement has moved from warning letters to criminal prosecution. On July 23, 2026 — the first day of the peptide vote — a seller of "research-only" GLP-1 peptides was sentenced to 21 months in federal prison.

For legitimate clinics, the direction of travel is clear: the lawful path to these substances runs through licensed prescribers and licensed compounding pharmacies, not the gray market.

Timeline: what to watch next

• Now: These peptides remain off the 503A list and are not lawfully compoundable. The FDA is not bound by the committee's recommendations.
• Next: If the FDA acts on the recommendations, expect a proposed rule, a public comment period, and then a final rule — realistically 2027 or later.
• Also pending: A second PCAC meeting covering additional peptides (including GHK-Cu) is expected before the end of February 2027.

Operators can track federal and state action in this category on the TrueEval Telehealth Enforcement Tracker and review sourcing partners on the US Compounding Pharmacy Map.

Frequently Asked Questions

Did the FDA approve BPC-157 or TB-500?

No. The FDA did not approve any peptide. An FDA advisory committee voted to recommend adding BPC-157, TB-500, and four other peptides to the Section 503A list of substances that compounding pharmacies may prepare with a prescription. That recommendation is non-binding and does not constitute drug approval or a finding of safety or effectiveness.

Are these peptides legal to buy or compound now?

No. As of July 2026 the peptides remain off the 503A Bulks List. Compounding them is not yet authorized, and buying peptides marketed "for research use only" for human use remains unlawful.

Which peptide was rejected?

Emideltide, also known as DSIP (delta sleep-inducing peptide), was the only one of the seven that did not receive a favorable recommendation, failing on a 6 to 7 vote with one abstention.

When could these peptides actually become available through pharmacies?

Only after the FDA completes formal rulemaking to add them to the 503A list — a process that realistically extends into 2027 or beyond, and which the FDA is not required to complete.